

**Table 3. Estimated vaccination coverage with selected vaccines and doses among adolescents 13–17 years, by year and sampling frame, National Immunization Survey-Teen, 2016-2017**

Vaccine	2016			2017		
	Single	Dual	Difference*	Single	Dual	Difference*
	% (95% CI)	% (95% CI)	Percentage Points (95% CI)	% (95% CI)	% (95% CI)	Percentage Points (95% CI)
HPV vaccine – all adolescents						
UTD †	43.7 (42.3 , 45.1)	43.4 (42.1 , 44.7)	0.3 (-0.3 , 0.7)	49.6 (48.1 , 51.1)	48.6 (47.3 , 49.9)	1.0 (0.4 , 1.4) §
≥1 dose	60.8 (59.4 , 62.2)	60.4 (59.2 , 61.6)	0.4 (-0.1, 0.9)	66.4 (65.1 , 67.7)	65.5 (64.3 , 66.7)	0.9 (0.4, 1.4) §
HPV vaccine – females						
UTD	50.0 (47.9 , 52.1)	49.5 (47.6 , 51.4)	0.5 (-0.4 , 1.0)	53.4 (51.3 , 55.5)	53.1 (51.2 , 55.0)	0.3 (-0.6 , 1.0)
≥1 dose	65.7 (63.8 , 67.6)	65.1 (63.4 , 66.8)	0.6 (0.0, 1.2)	68.9 (67.0 , 70.8)	68.6 (66.9 , 70.3)	0.3 (-0.4, 1.0)
HPV vaccine – males						
UTD	37.7 (35.8 , 39.6)	37.5 (35.8 , 39.2)	0.2 (-0.5 , 0.9)	46.0 (43.9 , 48.1)	44.3 (42.6 , 46.0)	1.7 (1.0 , 2.4)
≥1 dose	56.1 (54.1 , 58.1)	56.0 (54.3 , 57.7)	0.1 (-0.6, 0.8)	64.0 (62.1 , 65.9)	62.6 (61.0 , 64.2)	1.4 (0.7, 2.1) §
MenACWY						
≥1 dose	82.0 (80.8 , 83.2)	82.2 (81.2 , 83.2)	-0.2 (-0.5, 0.1)	85.3 (84.2 , 86.4)	85.1 (84.2 , 86.0)	0.2 (-0.2, 0.6)
≥2 doses	40.3 (37.0 , 43.6)	39.1 (36.1 , 42.1)	1.2 (0.0, 2.4)	44.2 (40.6 , 47.8)	44.3 (41.4 , 47.2)	-0.1 (-1.2, 1.0)

Vaccine	2016			2017		
	Single	Dual	Difference*	Single	Dual	Difference*
	% (95% CI)	% (95% CI)	Percentage Points (95% CI)	% (95% CI)	% (95% CI)	Percentage Points (95% CI)
Tdap						
≥1 dose	88.0 (86.9 , 89.1)	88.0 (87.1 , 88.9)	0.0 (-0.4, 0.4)	88.7 (87.7 , 89.7)	88.7 (87.8 , 89.6)	0.0 (-0.3, 0.3)
MMR						
≥2 doses	91.0 (90.2 , 91.8)	90.9 (90.2 , 91.6)	0.1 (-0.2, 0.4)	92.0 (91.2 , 92.8)	92.1 (91.4 , 92.8)	-0.1 (-0.3, 0.1)
Hepatitis B vaccine						
≥3 doses	91.6 (90.8 , 92.4)	91.4 (90.7 , 92.1)	0.2 (-0.1, 0.5)	91.9 (91.1 , 92.7)	91.9 (91.2 , 92.6)	0.0 (-0.2, 0.2)
Varicella vaccine						
History of varicella disease	15.2 (14.2 , 16.2)	15.2 (14.3 , 16.1)	0.0 (-0.3, 0.3)	13.1 (12.1 , 14.1)	13.2 (12.3 , 14.1)	-0.1 (-0.4, 0.2)
No history of varicella disease						
≥1 vaccine dose	95.0 (94.2 , 95.8)	95.0 (94.3 , 95.7)	0.0 (-0.2, 0.2)	95.6 (94.9 , 96.3)	95.5 (94.8 , 96.2)	0.1 (-0.1, 0.3)
≥2 vaccine dose	85.4 (84.2 , 86.6)	85.6 (84.6 , 86.6)	-0.2 (-0.6, 0.2)	88.5 (87.4 , 89.6)	88.6 (87.7 , 89.5)	-0.1 (-0.4, 0.2)
History of varicella disease or receipt of ≥2 varicella vaccine doses	87.6 (86.6 , 88.6)	87.8 (86.9 , 88.7)	-0.2 (-0.5, 0.1)	90.0 (89.1 , 90.9)	90.1 (89.3 , 90.9)	-0.1 (-0.4, 0.2)

Abbreviations: HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; Tdap = tetanus, diphtheria, and pertussis vaccine; MMR = measles, mumps, and rubella vaccine.

Note: “Single”=cell-phone, “Dual”=landline & cell-phone, CI=confidence interval

\*Difference=Single%-dual%

† HPV UTD includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.

§ Denotes statistically significant difference between single- and dual-frame estimates